In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia

Psychopharmacology

Volumn 124, Issue 1-2, 1996, Pages 154-158

  Martinot, J L ^a,c,d   Paillere Martinot M L ^d   Poirier, M F ^b   Dao Castellana, M H ^a   Loc'h, C ^a   Maziere B ^a  

^a DIF   (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c BICÊTRE HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Dopamine receptors; Neuroleptics; PET; Schizophrenia

Indexed keywords

AMISULPRIDE; BENZAMIDE DERIVATIVE; BROMINE 76; BROMOLISURIDE BR 76; DOPAMINE 2 RECEPTOR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBELLUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DOUBLE BLIND PROCEDURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REPRODUCIBILITY; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; BRAIN; FEMALE; HUMANS; MALE; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SULPIRIDE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029881047     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02245616     Document Type: Article

References (30)

1. Andreasen NC (1987) L'utilisation de la SANS et de la SAPS. Psychiatr Psychobiol 2:412
2. 76Br-bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab 6:131-136
3. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99:463-472
4. Boyer P, Lecrubier Y, Puech AJ (1990) Treatment of positive and negative symptoms: pharmacological approaches. In: Andreasen NC (ed) Schizophrenia: positive and negative symptoms and syndromes. Modern Problems in Pharmacopsychiatry. Karger, Basel, 24:152-174
5. Burl Dr, Creese I, Snyder SH (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196:326-328
6. Cambon H, Baron JC, Boulenger JP, Loc'h C, Zarifian E, Maziere B (1987) In vivo assay for neuroleptic receptor binding in the striatum. Positron tomography in humans. Br J Psychiatry 151:824-830
7. Carnoy P, Ravard S, Wemerman B, Soubrie P, Simon P (1986) Behavioral deficit induced by low doses of apomorphine in rats; evidence for a motivational and cognitive dysfunction which discriminates among neuroleptics. Pharmacol Biochem Behav 25:503-509
8. Costa e Silva JA (1989) Comparative double-blind study of amisulpride versus haloperidol in the treatment of acute psychotic states. In: Borenstein P, Boyer P, Braconnier A et al. (eds) Amisulpride. Expansion Scientifique Française, Paris, pp 93-104
9. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
10. 2 dopamine receptors studied by PET: J Cereb Blood Flow Metab 11:914-925
11. Delcker A, Schoon ML, Oczkowski B, Guertner HJ (1990) Amisulpride versus haloperidol in treatment of schizophrenic patients - results of a double-blind study. Pharmacopsychiatry 23:125-130
12. Dufour A, Desanti C (1989) Pharmacokinetics and metabolism of amisulpride. In: Borenstein P, Boyer P, Braconnier A et al. (eds) Amisulpride. Expansion Scientifique Française, Paris, pp 43-51
13. 2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76
14. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
15. Farde L, Nordström AL, Karlsson P, Halldin C, Sedvall G (1995) Positron emission tomography studies on dopamine receptors in schizophrenia. Clin Neuropharmacol 18 [suppl 1]:S121-S129
16. Guyon A, Abouly-Besse F, Biala Z, Puech AJ, Thiebot MH (1993) Potentiation by low doses of selected neuroleptics of food-induced place preference in rats. Psychopharmacology 110:460-466
17. Hillert A, Philip M, Gattaz WF, Sauer H, Adler G, Wetzel H, Benkerl O (1994) Amisulpride vs flupentixol in the treatment of schizophrenia with predominant positive symptomatology. Neuropsychopharmacology 10:31S
18. 3H-Spiperone binding sites in post-mortem brains from schizophrenic patients: relationships to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm 75:1-10
19. 2 receptor blockade and antipsychotic effects of neuroleptics. Preliminary study. Psychiatr Psychobiol 5:231-240
20. 76Br-bromolisuride. Br J Psychiatry 158:346-350
21. Maziere B, Loc'h C, Baron JC, Sgouropoulos P, Duquesnoy N, D'Antona R, Cambon H (1985) In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and 76 Br-bromospiperone. Eur J Pharmacol 114:267-272
22. 2 dopamine receptors. Eur J Pharmacol 127:239-247
23. 76Br-bromolisuride. In: Bunney WE, Hippius H, Laakmann G, Schmauss M (eds) Neuropsychopharmacology. Springer, Heidelberg. pp 409-417
24. 2-dopamine occupancy in relation to antipsychotic drug effect: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
25. Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152:130-133
26. Puech AJ, Simon P, Boissier JR (1978) Benzamides and classical neuroleptics: comparison of their actions using 6 apomorphine-induced effects. Eur J Pharmacol 50:291-300
27. 3 receptors. Neuropsychopharmacology 10:242S
28. Scatton B, Perrault G, Gonon R, Depoortere R, Sanger D, Schoemaker H (1995) Novel neuroleptics acting on presynaptic dopaminergic receptors. Neuropsychopharmacology 5:213S
29. 3) as a target for neuroleptics. Nature 347:146-151
30. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shive CY, Cooper TB, Brodie JD (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146:905-908